Citations

Showing 10 of 108119 citations.

Future use and implementation of AD blood biomarkers from a clinical and epidemiological perspective
Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.049764 Get It

AbstractBackgroundBlood‐based biomarkers for the diagnosis and prognosis of Alzheimer’s disease are now becoming a reality. Indeed, the first plasma amyloid‐beta blood test and algorithm is available for clinical use in some locations. With the very promising plasma phosphorylated tau 181 and 217 results in the past two years, it is likely additional tests will be approved in the near future. However, many questions remain as to how blood‐based biomarkers should best be used in the clinic, including how they should be utilized in the general population and among primary care physicians.MethodWe will discuss some of the key considerations and steps that must be taken before implementation in the clinic, especially in primary practice. Examples will be incorporated from the existing literature and data collected in the Mayo Clinic Study of Aging.ResultOne consideration includes the peripheral factors that might affect the levels of the biomarkers in blood including demographics (age and sex), and comorbidities. For example, a high body mass index is associated with a larger blood volume and renal disease can affect the clearance rate of the biomarker. Another consideration is the utility of a blood‐based biomarker among those with subjective memory complaints and the corresponding ethical implications and guidance for use that is needed. A third consideration is the context of use of blood‐based biomarkers in healthcare settings would could include general screening purposes, targeted screening in people at high risk and actively seeking counseling in primary care, and/or diagnosis in specialized/tertiary care.ConclusionBlood‐based biomarkers for the diagnosis and/or prognosis of Alzheimer’s disease and related disorders are much more feasible and less costly and invasive than a lumbar puncture for the collection of cerebrospinal fluid or amyloid and tau PET imaging. However, it is critical to address several concerns prior to implementing blood‐based biomarkers into the clinic, both in specialty and primary care settings, for the interpretation of the results and upmost consideration of the patient. Specific research actions will be needed to better understand the role of peripheral factors and the use of blood biomarkers in clinical care.
Mayo Test Drive: Reliability and construct validity of the Stricker Learning Span and Symbols Test on a self‐administered web‐based testing platform optimized for smartphone
Karstens, Aimee J. , Stricker, John L. , Fields, Julie A. , Karstens, Aimee James , Geske, Jennifer R. , Hassenstab, Jason , Mielke, Michelle M. , Stricker, Nikki H.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S6 | Pages: No page available

10.1002/alz.057614 Get It

AbstractBackgroundMayo Test Drive (MTD): Test Development through Rapid Iteration, Validation and Expansion, is a web‐based platform for remote self‐administered assessment for novel (Stricker Learning Span; SLS) and open access (Symbols Test) cognitive measures. The SLS is a computer adaptive word‐list memory test that matches test difficulty to user performance. The SLS visually presents words for learning exposures and 4‐choice recognition to test encoding across 5 trials. Symbols is a measure of processing speed being used in many remote assessment studies and typically employs a burst design; in MTD participants complete 4 trials (12‐items each). We examine validity and reliability of the SLS and Symbols via MTD.MethodForty‐five women enrolled in an ongoing study of the Sex‐Specific Effects of Endocrine Disruption on Aging and Alzheimer’s Disease were recruited via email or phone. The Auditory Verbal Learning Test (AVLT) and Digit Symbol Coding (Coding), administered in person within the past 2 years (Mean=11 months), were used to establish construct validity. Participants (91.3% White, Mean age=66.2 years, Mean education=15.3 years) were emailed a link to complete the SLS and Symbols remotely at their convenience on their own device and emailed to repeat testing after approximately 1 week. Pearson correlations (n=45) and 2‐way mixed intraclass correlation coefficients (ICC; n=42) determined construct validity and test‐retest reliability, respectively. Significance was set at p<.05.ResultAcross all test sessions initiated, 97% were successfully completed. Most were completed at home (92.6%; vs. at work or in a public space), and device type varied (48% smartphone, 2% tablet, 50% PC). Median session completion time was 15 minutes. SLS learning scores (max span, total correct trials 1‐5) significantly correlated with AVLT 1‐5 total (r’s .37‐.39) and AVLT Trial 5 (r’s .51‐.52). SLS delay significantly correlated with AVLT delay (r=0.45) and recognition (r=0.61). Symbols time‐based scores averaged across trials were significantly correlated with Coding (r’s=‐.48‐(‐).50). Test‐retest reliabilities across 2 sessions were high for SLS (ICC’s=.80‐.88) and Symbols (ICC’s=.81‐.82).ConclusionSLS and Symbols are valid and reliable self‐administered remote tests in older females. Future work will examine effects of Alzheimer’s disease neuroimaging biomarkers and risk factors on these tests.
Cognitive, neuropsychiatric and imaging comparisons between early‐onset and late‐onset Alzheimer’s disease participants from LEADS and ADNI3
Apostolova, Liana G. , Eloyan, Ani , Gao, Sujuan , Touroutoglou, Alexandra , Aisen, Paul , Borowski, Bret, Fagan, Anne M. , Gatsonis, Constantine , Kramer, Joel H. , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Rogalskı, Emily , Salloway, Stephen , Dickerson, Brad C., Iaccarino, Leonardo , Beckett, Laurel , Donohue, Michael , Foroud, Tatiana , Jack, Clifford R. , Koeppe, Robert A. , Saykin, Andrew J. , Toga, Arthur W. , Vemuri, Prashanthi , Day, Gregory S. , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Wolk, David A. , Wingo, Thomas S , Carrillo, María C. , Rabinovici, Gil D.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S6 | Pages: No page available

10.1002/alz.056676 Get It

AbstractBackgroundThe overarching goal of the Longitudinal Early‐onset Alzheimer Disease study (LEADS) is to optimally characterize early‐onset AD (EOAD) and establish an EOAD clinical trials network. Here we report the baseline demographic and imaging biomarker comparisons of the LEADS cohort to late‐onset AD (LOAD) subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI3).Method123 amyloid‐positive EOAD, 47 amyloid‐negative EOnonAD, 60 cognitively normal young controls were compared to 130 amyloid‐positive LOAD, 110 amyloid‐negative LOnonAD and 286 amyloid‐negative cognitively normal older controls. To account for the effect of cognitive aging between EO and LO populations, each cognitive measure was Z‐transformed. Cortical and hippocampal atrophy were quantified using W‐scores adjusted for age, sex and total intracranial volume. Z‐scores and W‐scores were compared using t‐test or Wilcoxson rank test as appropriate. All p‐values were corrected for multiple comparisons using the false discovery rate correction.ResultEOAD showed greater pathology burden and greater cortical atrophy (AD signature) relative to LOAD. EOAD also showed greater cognitive impairment across all cognitive tests. EOAD showed greater functional impairment, more depression but less neuropsychiatric behaviors overall compared to LOAD (Table 1 and Figure 1, all ps<0.05). Repeating the analyses stratified by cognitive stage (MCI/dementia) or CDR global rating (0.5/1) did not result in any major differences.EOnonAD differed from LOnonAD by also showing greater impairment on all cognitive and functional measures There were no significant differences in amyloid and tau burden, or atrophy W‐scores between these groups. EOnonAD were more depressed and showed more functional impairment compared to LOnonAD (Table 2 and Figure 2, all ps<0.05). Repeating the analyses split by cognitive stage (MCI/dementia) or CDR global rating (0.5/1) did not result in any major differences.ConclusionConsistent with our preexisting hypotheses, EOAD and EOnonAD perform much worse relative to their LO counterparts. EOAD also show greater pathological burden as expected. The reported analyses were done in chronological rather than disease time (time since disease onset). Benchmarking individuals along the disease spectrum might prove to be a better strategy especially when conducting analyses on rate of disease progression.
Waist‐hip ratio as a moderator of the effects of hormone therapy on cognitive function in recently menopausal women
James, Taryn T. , Simó, Carola A. Ferrer, Bouges, Shenikqua , Lambrou, Nickolas H., Hulle, Carol A. Van , Wyman, Mary F. , Salazar, Hector , Umucu, Emre , Cedars, Marcelle I. , Løbo, Rogerio A. , Neal‐Perry, Genevieve , Harman, S. Mitchell , Miller, Virginia M. , Gleason, Carey E. , Dowling, N. Maritza , Zuelsdorff, Megan L. , Johnson, Adrienne L. , Kara, Firat , Manson, JoAnn E. , Brinton, Eliot A. , Santoro, Nanette F. , Naftolin, Frederick , Pal, Lubna , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S6 | Pages: No page available

10.1002/alz.056539 Get It

AbstractBackgroundResearch on menopausal hormone therapy (MHT) for the reduction/prevention of cognitive decline or Alzheimer’s disease has been inconsistent. The Women’s Health Initiative Memory Study (WHIMS) revealed elevated incident cognitive impairment for women starting MHT after age >65 with oral conjugated equine estrogens (o‐CEE) treatment, especially among women with diabetes. Subsequently, the Cognitive and Affective substudy of the Kronos Early Estrogen Prevention Study (KEEPS‐Cog) found that MHT initiated soon after menopause caused neither cognitive benefit nor harm. Waist‐to‐hip ratio (WHR) is a measure of central adiposity and a surrogate marker for insulin resistance/prediabetes. To explore effects of MHT in insulin‐resistant states, in younger women, we analyzed WHR as a predictor of cognitive response to MHT in KEEPS‐Cog.MethodsKEEPS‐Cog randomized women less than 36‐months postmenopause to oCEE, transdermal 17‐β‐estradiol (tE2) or placebo for 48 months. Cognitive tests, completed at baseline, 18, 36, and 48 months post‐randomization were summarized as factor scores representing four cognitive domains: verbal learning and memory (VLM), auditory attention and working memory (AAWM), visual attention and executive function (VAEF), and speeded language and mental flexibility (SLMF). WHR, measured at screening and months 12, 36, and 48 was modeled as a time‐varying moderator of MHT on cognitive function over time. Education was included as a time‐invariant covariate.ResultsWHR decreased throughout the study in both the tE2 and oCEE groups compared to placebo. WHR was also inversely associated with all cognitive parameters at baseline. The inverse relationship of WHR on SLMF was significant at baseline and month 18, but decreased at month 48. The inverse relationship of WHR on VLM increased significantly over time. Models including interaction effects were significant for oCEE x WHR effects at months 18, 36, and 48 on SLMF, indicating better performance in MHT vs placebo arms. No other interaction effects were significant.ConclusionsWHR decreased with MHT, and was consistently associated with VLM through 4 years of MHT. Further, women on oCEE performed better on SLMF tasks at a given WHR. Differences between KEEPS‐Cog and WHIMS findings may be related to the timing of MHT administration, and effects on central adiposity/insulin resistance/prediabetes.
A remote smartphone cognitive testing battery for frontotemporal dementia: Completion rate, reliability, and validity
Staffaroni, Adam M. , Taylor, Jack C. , Clark, Annie L , Heuer, Hilary W. , Forsberg, Leah K. , Bahl, Riley, Manoochehri, Masood , Vento, Stephanie , Bajorek, Lynn, Ong, Elise, You, Michelle , Kramer, Joel H. , Rosen, Howard J. , Boxer, Adam L. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S6 | Pages: No page available

10.1002/alz.056136 Get It

AbstractBackgroundIn preparation for treatment trials in frontotemporal dementia (FTD), sensitive assessments to detect early clinical deficits and track longitudinal changes are needed. Remote digital data collection using smartphones may improve sensitivity to detect and follow abnormalities by allowing novel methods of data capture and more frequent assessments. Furthermore, remote evaluations can reduce patient and staff burden. Despite these benefits, little is known about the reliability and validity of self‐administered cognitive testing completed on smartphones.MethodWe investigated self‐administered smartphone cognitive tests from the ALLFTD Mobile App in a mixed sample of 45 participants, including 10 functionally intact older adults, 24 participants from families harboring pathogenic FTD mutations (asymptomatic n=14; mildly symptomatic n=10;), and 11 symptomatic FTD‐spectrum participants. A subset (n=15) was missing CDR®+NACC‐FTLD data but consensus diagnoses were available. Participants were asked to complete five tests that were repeated three times over eight days. Tests included versions of N‐back, Stroop, Flanker, and Go/No‐Go paradigms, and an adaptive spatial working memory test. Reliability was assessed using split‐half reliability (first testing session, 100 simulations) and intraclass correlations (ICC) across the three testing sessions. Linear models were fitted to evaluate the association of test performance with age and disease severity (CDR®+NACC‐FTLD Global and Box Scores), covarying for sex and education level. Models evaluating age associations excluded symptomatic participants.ResultParticipants completed 72.4% of available instruments. Split‐half reliability (range: 0.76 to 0.97) and ICCs (0.70 to 0.92) suggested adequate‐to‐excellent internal consistency and test‐retest reliability. Across the five tests, negative associations were observed with CDR®+NACC‐FTLD Box Scores (ßs = ‐0.24 to ‐0.77), and in clinically asymptomatic individuals, negative associations were observed with age (ßs = ‐0.43 to ‐0.88). Performance on all measures was worse in symptomatic participants compared to asymptomatic (p‐values<.05). Mildly symptomatic cases (CDR®+NACC‐FTLD=0.5) performed worse on Stroop, Flanker, and spatial working memory than asymptomatic participants (p‐values<.03). Flanker and Stroop tasks consistently showed the strongest reliability and validity findings.ConclusionSmartphone adaptations of common neuropsychological tests produced promising preliminary results. Strong associations with disease severity and age suggest these metrics may be valid for detecting clinically relevant cognitive changes, even in mildly symptomatic FTD.
An examination of atypical primary progressive aphasia variants
Boland, Sarah, Ali, Farwa , Martin, Peter R. , Graff‐Radford, Jonathan , Petersen, Ronald C. , Bigio, Eileen H. , Lowe, Val J. , Reichard, Ross R., Ertekin‐Taner, Nilüfer , Rademakers, Rosa , DeTure, Michael , Whitwell, Jennifer L. , Josephs, Keith A. , Botha, Hugo , Duffy, Joseph R. , Utianski, Rene L. , Machulda, Mary M. , Clark, Heather M. , Buciuc, Marina , Boeve, Bradley F. , Schwarz, Christopher G. , Senjem, Matthew L. , Reid, Robert I. , Jones, David T. , Knopman, David S. , Jack, Clifford R. , Ross, Owen A. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S6 | Pages: No page available

10.1002/alz.055305 Get It

AbstractBackgroundThe Neurodegenerative Research Group (NRG) at Mayo clinic has followed patients with degenerative speech and/or language disorders for over a decade. In this presentation I will present data from this cohort to inform a broader discussion about the importance of apraxia of speech (AOS) and its subtypes, heterogeneity within the agrammatic PPA variant, and perils of mixed phenotypes.MethodWe reviewed the NRG database to identify patients who initially presented with isolated (PPAOS), AOS in conjunction with agrammatic aphasia (AOS‐PAA), isolated agrammatic aphasia (PAA), and patients who had PAA or AOS overlapping with another degenerative diagnosis. Data from the following clinical instruments were abstracted: WAB AQ (aphasia severity), UPDRS III (parkinsonism), WAB Praxis (ideomotor apraxia), and the MoCA (cognitive ability). We assessed the effect of baseline diagnosis and AOS subtype on these outcomes over time using Bayesian linear mixed effects models. We qualitatively reviewed longitudinal diagnostic trajectories. Preliminary analyses were done on available autopsy data.ResultPAA was associated with greater aphasia at baseline and more rapid decline; PPAOS was associated with normal language at baseline and slow decline; and PAA‐AOS with intermediate baseline aphasia and decline. However, for those with AOS longitudinal decline differed based on AOS subtype: prosodic PPAOS was associated with the slowest decline and phonetic PAA‐AOS with the fastest. Some patients met criteria for non‐PPA disorders during follow up. However, compared to patients who met criteria for these disorders at enrollment, the speech/language‐first patients remained qualitatively distinct, and neither resembled the cases that were mixed at onset. Preliminary autopsy data suggests that AOS is predictive of tau and that the specific tauopathy may be related to the initial syndrome and AOS subtype.ConclusionThe differences between PAA, PAA‐AOS and PPAOS suggest that these disorders should not be lumped. In fact, the longitudinal trajectories are sufficiently different that doing so would add noise to observational and interventional studies. Instead, more detailed phenotyping, including AOS subtype, can aid prognostication and may improve prediction of the underlying pathology. Finally, caution should be exercised when considering PPAOS and PPA patients for other FTLD diagnostic categories.
Clinical features that differentiate young‐onset AD from young‐onset FTLD: An examination of the NACC UDS 3.0 and FTLD Module
Dev, Sheena I. , Quimby, Megan , Eloyan, Ani , Staffaroni, Adam M. , Rascovsky, Katya, Weıntraub, Sandra , Fields, Julie A. , Rankin, Katherine P. , Heuer, Hilary W. , Forsberg, Leah K. , Brushaber, Danielle , Rosen, Howard J. , Boxer, Adam L. , Apostolova, Liana G. , Dickerson, Brad C., Bahl, Riley, Wong, Bonnie , Kukull, Walter A. , Boeve, Bradley F. , Carrillo, María C. , Rabinovici, Gil D.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S6 | Pages: No page available

10.1002/alz.055209 Get It

AbstractBackgroundClinicopathologic studies reported that the NACC Uniform Dataset (UDS) 2.0 core measures do not adequately differentiate patients who ultimately died of Frontotemporal Lobar Degeneration (FTLD) from Alzheimer’s disease (AD). The FTLD Module (FTLD‐MOD) assesses core features of behavioral variant FTD (bvFTD) and primary progressive aphasia (PPA). Initial investigations suggest that the FTLD‐MOD improves discrimination between biomarker‐supported bvFTD and typical late‐onset AD, and that clinically diagnosed PPA participants performed worse than bvFTD on all FTLD‐MOD language tasks. However, the utility of these measures in the differential diagnosis of AD vs. major FTLD syndromes in young‐onset cases remains underexplored.MethodWe examined participants with age‐of‐onset < 65 years in the ARTFL‐LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) consortium and the Longitudinal Early Onset AD Study (LEADS). 115 bvFTD, 53 semantic variant PPA (svPPA), 29 non‐fluent variant PPA (nfvPPA) and 124 early‐onset AD (eoAD) cases completed the UDS3 and FLTD‐MOD. Linear regression analyses measured group differences in FLTD‐MOD raw scores and UDS3 neuropsychological z‐scores after accounting for group differences in demographic variables and global severity ratings. Alpha was 0.05 with Bonferroni corrections.ResultsParticipants with eoAD demonstrated the most impaired scores on tasks of attention, working memory, and processing speed, including Digit Span Backward (z=‐1.87) and Trails A (z=‐3.82). They also demonstrated difficulty on FTLD‐MOD language tasks with a working memory requirement (sentence repetition raw=3.68/5) and, as expected, memory (story delayed recall z=‐2.4z). svPPA performed the worst on FTLD‐MOD and UDS3 tasks assessing semantic memory, especially naming (all p’s ≤ 0.03). nfvPPA performed worst on sentence reading, sentence repetition, and letter fluency (all p’s ≤ 0.02). Consistent with previous work, these measures differentiate between bvFTD and PPA variants. However, relative to eoAD, bvFTD was equivalent (Trails B: bvFTDz=‐3.8, eoADz=‐3.82; p=0.12) or outperformed (sentence repetition: bvFTD=4.22/5, eoAD=3.68/5; p<0.001) the eoAD group on all tasks.ConclusionsWe undertook this analysis to compare performance of the major young‐onset sporadic AD and FTLD clinical syndromes in the ALLFTD and LEADS studies. Results demonstrate relatively distinct cognitive profiles among eoAD, svPPA, and nfvPPA, but not in bvFTD. Future analyses will include FTLD‐MOD behavioral symptom questionnaires to assess their utility in differentiating bvFTD.
Neuropsychological test performance in former college and professional American football players
Culhane, Julia, Banks, Sarah J. , Balcer, Laura J. , Bernick, Charles , Palmisano, Joseph , Reiman, Eric M. , Alosco, Michael L. , Barr, William , Wethe, Jennifer V. , Miller, Justin B. , Adler, Charles H. , Tripodis, Yorghos , Cummings, Jeffrey L. , Shenton, Martha E. , Stern, Robert A.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S6 | Pages: No page available

10.1002/alz.054455 Get It

AbstractBackgroundRepetitive head impacts from American football have been associated with long‐term cognitive symptoms. The late neuropsychological profiles of this population is not well‐characterized. Research has relied on retrospective informant reports and/or has been small samples of former professional players. We describe objective neuropsychological test performance in former college and professional American football players.MethodsMale (45‐74 years) former National Football League (n=107) and college football players (n=59) from the DIAGNOSE‐CTE Research Project completed a neuropsychological test battery, Functional Activities Questionnaire (FAQ) and Quick Dementia Rating Scale (QDRS). Neuropsychological test scores were converted to T‐scores using age, sex, and/or education‐adjusted normative data. T‐scores<35 defined impairment. Participants were enrolled across the spectrum of symptom severity (asymptomatic to dementia). Individuals without decisional capacity were excluded. Participants with missing data (n=4) and who scored <45 on Test of Memory Malingering Trial 2 (n=10) were excluded.Results108 (65.1%) identified as White and 53 (31.9%) as Black. Mean education years was 16.76 (SD=1.48). Fourteen (8.4%) and 6 (3.6%) reported diagnostic history of ADHD and learning disability, respectively. Average Montreal Cognitive Assessment score was 24.96 (SD=3.17); 85 (51.2%) scored <26. Impairment rates were highest for learning and episodic memory. On Neuropsychological Assessment Battery List Learning, 29.5% were impaired on Immediate recall, 36.1% on Short Delay, and 44.0% on Long Delay Recall. Impairment rates for Craft Story Immediate and Delayed Recall (Paraphrase) were 15.7% and 18.7%, respectively. 19.9% and 15.7% were impaired on learning and delayed recall of the Brief Visuospatial Memory Test‐Revised. Impairments were frequent on the Multilingual Naming Test (20.5%), Trail Making Test Parts B (19.3%) and A (18.1%), Animal Fluency (15.7%), and Number Span Backward (15.1%). Impairments were less common (<10%) for phonemic fluency, planning, basic attention, and visual‐perceptual abilities, Mean FAQ was 3.11 (SD=5.14); 23 (13.9%) had an FAQ >9. Based on QDRS scores, 66 (39.8%) had mild cognitive impairment, 44 (26.5%) mild dementia, and 6 (3.6%) moderate dementia.ConclusionsIn these former American football players, neuropsychological impairments were most frequent in episodic memory, followed by confrontation naming and executive function. Further research is needed to delineate this population’s unique neuropsychological profile.
Preliminary diagnostic criteria for prodromal behavioral variant frontotemporal dementia: Mild behavioral and/or cognitive impairment
Gottesman, Reena , Manoochehri, Masood , Forsberg, Leah K. , Heuer, Hilary W. , Boxer, Adam L. , Rosen, Howard J. , Cosentino, Stephanie , Rascovsky, Katya, Huey, Edward D. , Barker, Megan S. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S6 | Pages: No page available

10.1002/alz.054221 Get It

AbstractBackgroundAt present, no research criteria exist for the diagnosis of prodromal behavioral variant frontotemporal dementia (bvFTD). Leveraging data from carriers of pathogenic genetic mutations as a proxy for frontotemporal lobar degeneration pathology, we sought to develop and test a proposed set of research criteria for prodromal bvFTD, termed “Mild Behavioral and/or Cognitive Impairment in bvFTD” (MBCI‐FTD).MethodParticipants included 68 carriers of a pathogenic mutation in microtubule‐associated protein tau (MAPT), or progranulin (GRN), or a repeat expansion in chromosome 9 open reading frame 72 (C9orf72), with mild behavioral and/or cognitive changes. Based on extensive clinical workup, the prodromal mutation carrier group was divided into a Development Group (N=22) and a Test Group (N=46). The Development Group was selected to be the subset of the prodromal mutation carriers for whom we had longitudinal evidence of conversion to a bvFTD phenotype, and were used to develop the criteria. The Test Group was the remainder of the prodromal mutation carriers (e.g., single visits only) and was used to validate the criteria. Familial non‐carriers were included as controls (N=165).ResultFrequencies of behavioral and neuropsychiatric features, neuropsychological deficits, and social cognitive dysfunction in prodromal mutation carriers and non‐carrier controls were assessed. Based on sensitivity and specificity analyses, seven core features were identified: apathy without moderate‐severe dysphoria, behavioral disinhibition, irritability/agitation, reduced empathy/sympathy, repetitive behaviors (simple and/or complex), joviality/gregariousness, and appetite changes/hyperorality. Supportive features include a neuropsychological profile of impaired executive function or naming with intact orientation and visuospatial skills, reduced insight for cognitive or behavioral changes, and poor social cognition. Three core features or two core features plus one supportive feature are required for the diagnosis of Possible MBCI‐FTD; Probable MBCI‐FTD requires imaging or biomarker evidence, or a pathogenic genetic mutation. The proposed MBCI‐FTD criteria correctly classified 95% of the Development Group of prodromal mutation carriers, and 41% of the Test Group, with a false positive rate of <10%.ConclusionWe present the first diagnostic criteria for prodromal bvFTD. Future research should prioritize establishing generalizability to non‐genetic cases, and testing the specificity of these criteria against psychiatric, neurologic and other neurodegenerative diseases.
Cancer survivors have a lower frequency of dementia in the 95+ oldest‐old
Lachner, Christian , Camsari, Gamze Balci, Ertekin‐Taner, Nilüfer , Thompson, E. Aubrey , Petersen, Ronald C. , Lucas, John A. , Reichard, Ross R., Graff‐Radford, Neill R. , Boeve, Bradley F. , Dickson, Dennis W. , Knopman, David S. , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S6 | Pages: No page available

10.1002/alz.052376 Get It

AbstractBackgroundAdvancing age is an important risk factor for dementia and cancer. An inverse association between these conditions has been described, yet caution from potential biases/confounders is warranted. Dementia and cancer may represent a spectrum of opposing dysregulated degenerative (apoptosis) and growth (proliferative) pathways respectively (Driver, 2014). Risk or resiliency factors affecting these pathways may influence cognitive outcomes in the oldest‐old. We sought to investigate demographics, clinical characteristics, and the impact of medical comorbidity on possible risk‐resiliency factors for neurodegeneration in nondemented and demented oldest‐old who died and underwent autopsy.MethodMedical records of 161 decedents (female n=134) from the Mayo Clinic 95+ year‐old cohort (age range 95‐106 years‐old) were reviewed. Groups consisting of nondemented (n=72) and demented (n=89) decedents were stratified and compared according to demographics and clinical variables, including history of cancer. Autopsy and neuropathologic evaluation was also conducted.ResultAge at death, sex, race, and education showed no differences between nondemented and demented decedents. History of cancer was higher in nondemented (57%) compared to demented decedents (30%) (p=0.002). APOE ε4 allele presence did not differ amongst groups, while APOE ε2 allele was more common in the nondemented group (p=0.026). History of coronary artery disease was higher in the nondemented (p=0.033). No differences were observed in other vascular risk factors, alcohol use, or depression. Smoking history approached significance and was higher in nondemented compared to demented (p=0.068). MMSE scores were higher in the nondemented group (p<0.001). Neuropathology findings included a lower Braak tangle staging in nondemented (median=III) compared to demented (median=V) groups (p<0.001) and less frequent diffuse plaques observed in the nondemented (67%) compared with those demented (93%) (p<0.001).ConclusionDementia is less frequent among cancer survivors in the 95+ oldest‐old. Disease‐related mechanisms associated with malignancy and surviving it may be protective against neurodegeneration in the oldest old.